28 August 2021 in European Journal of Clinical Pharmacology
16 June 2025 in Clinical and Applied Thrombosis/Hemostasis
Purpose: This study aims to develop a scoring system tailored for Asian populations through quantifying VTE risk in a cohort of hospitalized cancer patients receiving immune checkpoint inhibitors. Methods: We retrospectively analyzed 1171 patients treated with PD-1/PD-L1 inhibitors at Zhongshan Hospital (Xiamen), Fudan University between January 2021 and December 2023. We gathered information on every patient from the electronic database of the hospital and follow-up.The collected data were statistically analyzed to obtain risk factors for for VTE and validation of the score. Finally, we validated the precision of the model in prediction. Results: Based on these findings, we developed the L2HSDK score,that identified seven independent risk factors for VTE:liver cancer, smoking, diabetes mellitus, liver dysfunction, cardiovascular history, and a Khorana Risk Score ≥ 3. The patients were divided into low, moderate, and high VTE risk groups. Significant differences in VTE incidence were observed across these groups, with the high-risk group showing a markedly higher risk. The validation of the model demonstrates the precision of the L2HSDK score in prediction. Conclusion: The L2HSDK score offers a more precise and tailored method for assessing VTE risk in cancer patients receiving PD-1/PD-L1 inhibitors therapy in mainland China, surpassing the widely used Khorana Risk Score by accounting for regional and treatment-specific factors.
8 January 2024 in Health Science Reports
Background and Aims: To construct a bleeding events prediction model of nonvalvular atrial fibrillation (NVAF) patients receiving rivaroxaban.Methods: We conducted a retrospective cohort study in patients with NVAF who received rivaroxaban from June 2017 to March 2019. Demographic information and clinical characteristics were obtained from the electronic medical system. Univariate analysis was used to find the primary predictive factors of bleeding events in patients receiving rivaroxaban. Multiple analysis was conducted to screen the primary independent predictive factors selected from the univariate analysis. Finally, the independent influencing factors were applied to build a prediction model by using R software; then, a nomogram was established according to the selected variables visually, and the sensitivity and specificity of the model was evaluated.Results: Twelve primary predictive factors were selected by univariate analysis from 46 variables, and multivariate analysis showed that older age, higher prothrombin time (PT) values, history of heart failure and stroke were independent risk factors of bleeding events. The area under curve (AUC) for this novel nomogram model was 0.828 (95% CI: 0.763–0.894). The mean AUC over 10‐fold stratified cross‐validation was 0.787, and subgroup analysis validation also showed a satisfied AUC. In addition, the decision curve analysis showed that the PT in combination with CHA2DS2‐VASc and HASBLED was more practical and accurate for predicting bleeding events than using CHA2DS2‐VASc and HASBLED alone.Conclusions: PT in combination with CHA2DS2‐VASc and HASBLED could be considered as a more practical and accurate method for predicting bleeding events in patients taking rivaroxaban.
1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Purpose: Ticagrelor is an antiplatelet drug, and its use increases the risk of bleeding. Coronary artery disease is significantly influenced by the widespread occurrence of diabetes mellitus. In order to decrease the incidence of clinical adverse events, a novel bleeding and thrombosis score is developed in this research. Methods: We conducted a retrospective analysis of patient data from two medical centers who were diagnosed with diabetes mellitus and treated with ticagrelor. We gathered information on every patient from the electronic database of the hospital and follow-up. The collected data were statistically analyzed to obtain risk factors for bleeding and ischemic events. Results: A total of 851 patients with diabetes mellitus who have been administered ticagrelor are included in our investigation. A total of 76 patients have bleeding events and 80 patients have ischemic events. The analysis of multiple variables indicates that characteristics like the age of >65, having a previous occurrence of bleeding, experiencing anemia, using aspirin, and taking atorvastatin are linked to a higher likelihood of bleeding. Additionally, the age of >65, smoking, having a history of blood clots, and having a BMI ≥ 30 are found to increase the risk of ischemia. Conclusion: The A4B score established in this study was better than the HAS-BLED score,and the same is true for the ABST score to the CHA2DS-VASc score. This new risk assessment model can potentially detect patients who are at high risk for bleeding and ischemic events. For high-risk patients, the dose of ticagrelor can be adjusted appropriately or the medication can be adjusted.(2023-09-11, ChiCTR2300075627)